CDKN1B (pT187) Antibody

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
Description
CDKN1B (pT187) Antibody is a Rabbit Polyclonal antibody against CDKN1B (pT187). Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Positive regulator of cyclin D-dependent kinases such as CDK4. Regulated by phosphorylation and degradation events.
Documents del producto
Product specifications
Category | Primary Antibodies |
Immunogen Target | CDKN1B (pT187) |
Host | Rabbit |
Reactivity | Human |
Recommended Dilution | WB: 1/500 - 1/1000. Optimal dilutions/concentrations should be determined by the end user. |
Clonality | Polyclonal |
Conjugation | Unconjugated |
Isotype | IgG |
Purification | Purified by affinity chromatography. |
Size 1 | 20 µl |
Size 2 | 100 µl |
Size 3 | 2 × 100 µl |
Form | Liquid |
Tested Applications | WB |
Buffer | PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol. |
Availability | Shipped within 5-10 working days. |
Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
Dry Ice | No |
UniProt ID | P46527 |
Gene ID | 1027 |
Background | Antibody anti-CDKN1B |
Status | RUO |
Note | Concentration: > 0.2 mg/ml - |
Descripción
Related Products

Human CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
Mouse CDKN1B (Cyclin Dependent Kinase Inhibitor 1B) ELISA Kit
Ver Producto
CDKN1B antibody
CDKN1B, also named as P27 or KIP1, is a cyclin-dependent kinase inhibitor, which shares a limited similarity with CDK inhibitor CDKN1A/p21. P27 binds to and prevents the activation of cyclin E-CDK2 or cyclin D-CDK4 complexes, and thus controlling cell cycle progression at G1. The degradation of this protein, which is triggered by its CDK dependent phosphorylation and subsequent ubiquitination by SCF complexes, is required for the cellular transition from quiescence to the proliferative state. Downregulation of P27 has been implicated in the progression of several malignancies, including lung cancer, hepatocellular carcinoma, salivary cancer, oral squamous cell carcinomas, and gastric cancer.
Ver Producto